Pentoxifylline	pentoxifylline	S_chemical	O
(	(	O	O
Trental	trental	O	O
)	)	O	O
does	does	O	O
not	not	O	O
inhibit	inhibit	O	O
dipyridamole-induced	dipyridamole-induced	O	O
coronary	coronary	O	B_disease
hyperemia	hyperemia	O	S_disease
:	:	O	O
implications	implications	O	O
for	for	O	O
dipyridamole-thallium-201	dipyridamole-thallium-201	S_chemical	O
myocardial	myocardial	O	O
imaging	imaging	O	O
.	.	O	O

Dipyridamole-thallium-201	dipyridamole-thallium-201	S_chemical	O
imaging	imaging	O	O
is	is	O	O
often	often	O	O
performed	performed	O	O
in	in	O	O
patients	patients	O	O
unable	unable	O	O
to	to	O	O
exercise	exercise	O	O
because	because	O	O
of	of	O	O
peripheral	peripheral	O	B_disease
vascular	vascular	O	I_disease
disease	disease	O	I_disease
.	.	O	O

Many	many	O	O
of	of	O	O
these	these	O	O
patients	patients	O	O
are	are	O	O
taking	taking	O	O
pentoxifylline	pentoxifylline	S_chemical	O
(	(	O	O
Trental	trental	O	O
)	)	O	O
,	,	O	O
a	a	O	O
methylxanthine	methylxanthine	B_chemical	O
derivative	derivative	I_chemical	O
which	which	O	O
may	may	O	O
improve	improve	O	O
intermittent	intermittent	O	B_disease
claudication	claudication	O	I_disease
.	.	O	O

Whether	whether	O	O
pentoxifylline	pentoxifylline	S_chemical	O
inhibits	inhibits	O	O
dipyridamole-induced	dipyridamole-induced	O	O
coronary	coronary	O	B_disease
hyperemia	hyperemia	O	S_disease
like	like	O	O
other	other	O	O
methylxanthines	methylxanthines	S_chemical	O
such	such	O	O
as	as	O	O
theophylline	theophylline	S_chemical	O
and	and	O	O
should	should	O	O
be	be	O	O
stopped	stopped	O	O
prior	prior	O	O
to	to	O	O
dipyridamole-thallium-201	dipyridamole-thallium-201	S_chemical	O
imaging	imaging	O	O
is	is	O	O
unknown	unknown	O	O
.	.	O	O

Therefore	therefore	O	O
,	,	O	O
we	we	O	O
studied	studied	O	O
the	the	O	O
hyperemic	hyperemic	O	O
response	response	O	O
to	to	O	O
dipyridamole	dipyridamole	S_chemical	O
in	in	O	O
seven	seven	O	O
open-chest	open-chest	O	O
anesthetized	anesthetized	O	O
dogs	dogs	O	O
after	after	O	O
pretreatment	pretreatment	O	O
with	with	O	O
either	either	O	O
pentoxifylline	pentoxifylline	S_chemical	O
(	(	O	O
0	0	O	O
,	,	O	O
7.5	7.5	O	O
,	,	O	O
or	or	O	O
15	15	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
or	or	O	O
theophylline	theophylline	S_chemical	O
(	(	O	O
3	3	O	O
mg/kg	mg/kg	O	O
i.v	i.v	O	O
.	.	O	O
)	)	O	O
.	.	O	O

Baseline	baseline	O	O
circumflex	circumflex	O	O
coronary	coronary	O	O
blood	blood	O	O
flows	flows	O	O
did	did	O	O
not	not	O	O
differ	differ	O	O
significantly	significantly	O	O
among	among	O	O
treatment	treatment	O	O
groups	groups	O	O
.	.	O	O

Dipyridamole	dipyridamole	S_chemical	O
significantly	significantly	O	O
increased	increased	O	O
coronary	coronary	O	O
blood	blood	O	O
flow	flow	O	O
before	before	O	O
and	and	O	O
after	after	O	O
7.5	7.5	O	O
or	or	O	O
15	15	O	O
mm/kg	mm/kg	O	O
i.v	i.v	O	O
.	.	O	O

pentoxifylline	pentoxifylline	S_chemical	O
(	(	O	O
p	p	O	O
less	less	O	O
than	than	O	O
0.002	0.002	O	O
)	)	O	O
.	.	O	O

Neither	neither	O	O
dose	dose	O	O
of	of	O	O
pentoxifylline	pentoxifylline	S_chemical	O
significantly	significantly	O	O
decreased	decreased	O	O
the	the	O	O
dipyridamole-induced	dipyridamole-induced	O	O
hyperemia	hyperemia	O	S_disease
,	,	O	O
while	while	O	O
peak	peak	O	O
coronary	coronary	O	O
blood	blood	O	O
flow	flow	O	O
was	was	O	O
significantly	significantly	O	O
lower	lower	O	O
after	after	O	O
theophylline	theophylline	S_chemical	O
(	(	O	O
p	p	O	O
less	less	O	O
than	than	O	O
0.01	0.01	O	O
)	)	O	O
.	.	O	O

We	we	O	O
conclude	conclude	O	O
that	that	O	O
pentoxyifylline	pentoxyifylline	S_chemical	O
does	does	O	O
not	not	O	O
inhibit	inhibit	O	O
dipyridamole-induced	dipyridamole-induced	O	O
coronary	coronary	O	B_disease
hyperemia	hyperemia	O	S_disease
even	even	O	O
at	at	O	O
high	high	O	O
doses	doses	O	O
.	.	O	O

